MarketScreener Homepage > Equities > Swiss Exchange > Roche Holding AG ROG CH0012032048

Report

Delayed Swiss Exchange - 04/09 11:30:02 am
309.65	CHF		+0.81%

04/09

CHUGAI PHARMACEUTICAL : Conducts Disease Awareness Activities Internally and Externally in Supporting the World Hemophilia Day

04/09

Regeneron Pharma Covid-19 Treatment Recommended by National Institutes of Health

04/08

Biogen Licenses Actemra Biosimilar Candidate From Bio-Thera Solutions

Summary

Quotes 5-day view Delayed Quote.

Delayed Swiss Exchange

04/01/2021	04/06/2021	04/07/2021	04/08/2021	04/09/2021	Date
305.4(c)	305.3(c)	302.2(c)	307.15(c)	309.65(c)	Last
961 132	1 003 282	1 326 517	1 164 061	1 021 222	Volume
-0.02%	-0.03%	-1.02%	+1.64%	+0.81%	Change

More quotes

Financials

Sales 2021	60 335 M 65 234 M 65 234 M
Net income 2021	14 738 M 15 935 M 15 935 M
Net cash position 2021	4 797 M 5 187 M 5 187 M
P/E ratio 2021	17,8x
Yield 2021	3,05%

Sales 2022	62 347 M 67 410 M 67 410 M
Net income 2022	15 890 M 17 180 M 17 180 M
Net cash position 2022	12 336 M 13 338 M 13 338 M
P/E ratio 2022	16,7x
Yield 2022	3,16%

Capitalization	267 B 288 B 288 B
EV / Sales 2021	4,34x
EV / Sales 2022	4,08x
Nbr of Employees	101 465
Free-Float	82,6%

More Financials

Company

Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The...

Sector

Pharmaceuticals

Calendar

04/21 | 08:00am

Sales and Revenue Call

More about the company

Notations Surperformance© of Roche Holding AG

Trading Rating :

Investor Rating :

More Ratings

All news about ROCHE HOLDING AG

04/09	CHUGAI PHARMACEUTICAL : Conducts Disease Awareness Activities Internally and Ex..	AQ
04/09	Regeneron Pharma Covid-19 Treatment Recommended by National Institutes of Hea..	DJ
04/08	Biogen Licenses Actemra Biosimilar Candidate From Bio-Thera Solutions	DJ
04/08	ROCHE : to Present New Data on New, Potential Treatments for Neurological Disor..	MT
04/08	ROCHE : New Genentech Data at 2021 AAN Highlight Impact and Breadth of Expandin..	BU
04/08	PRESS RELEASE : New Roche data at 2021 AAN -3-	DJ
04/08	ROCHE : New Roche data at 2021 AAN highlight impact and breadth of expanding ne..	AQ
04/08	PRESS RELEASE : New Roche data at 2021 AAN -2-	DJ
04/08	PRESS RELEASE : New Roche data at 2021 AAN highlight impact and breadth of expa..	DJ
04/07	ROCHE : MHRA - Early Access continues during the coronavirus (COVID-19) pandemi..	AQ
04/07	Global markets live: Morgan Stanley, Toshiba, Roche…
04/07	ROCHE : Launches Elecsys Anti-p53 Test to Help in Diagnosing Cancer Types	MT
04/07	ROCHE : launches Elecsys Anti-p53 immunoassay to aid diagnosis of various cance..	AQ
04/07	PRESS RELEASE : Roche launches Elecsys Anti-p53 immunoassay to aid diagnosis of..	DJ
04/07	ROCHE HOLDINGS AG : JP Morgan reiterates its Neutral rating	MD

More news

News in other languages on ROCHE HOLDING AG

04/09	ROCHE : le NIH recommande un cocktail corona de Regeneron
04/09	ROCHE-PARTNER REGENERON : Corona-Cocktail von NIH nachdrücklich empfohlen
04/09	Aktien Schweiz etwas fester - US-Vorgaben stützen
04/08	Aktien Schweiz freundlich - US-Notenbank beruhigt Anleger
04/08	Roche présente des données de son portefeuille de neurosciences aux Etats-Uni..

More news

Analyst Recommendations on ROCHE HOLDING AG

04/07	ROCHE HOLDINGS AG : JP Morgan reiterates its Neutral rating	MD
03/24	ROCHE HOLDINGS AG : Barclays gives a Buy rating	MD
03/24	ROCHE : Bank Vontobel Lifts Price Target on Roche, Maintains Buy Recommendation	MT

More recommendations

Stock Trading Strategies

	ROCHE HOLDING AG - 2020
Close to an important medium term support level

BUY

More Stock Trading Analysis

Provided by Scoopnest.com

Analysis

Roche buys GenMark for $1.8 million to challenge test rivals